"Not So Different:" The Community Oncology Perspective on Drug Pricing Proposals and Biosimilars

March 31, 2019

The recent weeks and months have seen a number of policy proposals from the Trump administration that impact community oncologists. On this week's podcast, Laura Joszt, associate editorial director of The Center for Biosimilars®, caught up with Ted Okon, MBA, executive director of the Community Oncology Alliance.

The recent weeks and months have seen a number of policy proposals from the Trump administration that impact community oncologists. On this week's podcast, Laura Joszt, associate editorial director of The Center for Biosimilars®, caught up with Ted Okon, MBA, executive director of the Community Oncology Alliance (COA). In this discussion, you'll hear Okon discuss COA's position on the Trump administration's proposals on pharmacy benefit manager rebates and the International Pricing Index for prescription drugs. He also tackles the question of how community oncologists are preparing for anticancer biosimilars, as well as the role of biosimilars in the Oncology Care Model.

To read more about COA's Biosimilars Committee, click here.

Related Content:

Podcasts

x